IPSEN – Buy-back programme – Art 5 of MAR – Week 25 – 2024
- 25 June 2024 - 1 mins read
Aggregated presentation by day and by market
| Purchases of own shares from June 17th to 21th 2024 | ||||||
| Name of the Issuer | Identity code of the Issuer | Day of the transaction | Identity code of the financial instrument | Total daily volume (in number of shares) | Daily weighted average purchase price of the shares | Market (MIC Code) |
| IPSEN | 549300M6SGDPB4Z94P11 | 17/06/2024 | FR0010259150 | 6 600 | 120,3723 | XPAR |
| IPSEN | 549300M6SGDPB4Z94P11 | 17/06/2024 | FR0010259150 | 2 400 | 120,4326 | CEUX |
| IPSEN | 549300M6SGDPB4Z94P11 | 17/06/2024 | FR0010259150 | 515 | 120,4006 | TQEX |
| IPSEN | 549300M6SGDPB4Z94P11 | 17/06/2024 | FR0010259150 | 485 | 120,4344 | AQEU |
| IPSEN | 549300M6SGDPB4Z94P11 | 18/06/2024 | FR0010259150 | 7 537 | 119,3154 | XPAR |
| IPSEN | 549300M6SGDPB4Z94P11 | 18/06/2024 | FR0010259150 | 2 463 | 119,0330 | CEUX |
| IPSEN | 549300M6SGDPB4Z94P11 | 19/06/2024 | FR0010259150 | 4 000 | 117,7254 | XPAR |
| IPSEN | 549300M6SGDPB4Z94P11 | 20/06/2024 | FR0010259150 | 5 743 | 117,1677 | XPAR |
| IPSEN | 549300M6SGDPB4Z94P11 | 20/06/2024 | FR0010259150 | 1 957 | 117,1431 | CEUX |
| IPSEN | 549300M6SGDPB4Z94P11 | 20/06/2024 | FR0010259150 | 100 | 117,0000 | TQEX |
| IPSEN | 549300M6SGDPB4Z94P11 | 20/06/2024 | FR0010259150 | 200 | 116,9350 | AQEU |
| IPSEN | 549300M6SGDPB4Z94P11 | 21/06/2024 | FR0010259150 | 2 737 | 115,3567 | XPAR |
| IPSEN | 549300M6SGDPB4Z94P11 | 21/06/2024 | FR0010259150 | 1 263 | 115,0259 | CEUX |
| TOTAL | 36 000 | 118,4864 | ||||
Attachment
11 July 2024
6 mins read
Ipsen and Foreseen Biotechnology announce exclusive global licensing agreement for antibody-drug conjugate with first-in-class potential
09 July 2024
1 mins read
IPSEN – Buy-back programme – Art 5 of MAR – Week 27 – 2024
09 July 2024
1 mins read
Ipsen – June 2024 – Monthly information relative to the total number of voting rights and shares composing the share capital
08 July 2024
1 mins read
Half-year statement of IPSEN liquidity agreement – 2024 06 30
02 July 2024
1 mins read
IPSEN – Buy-back programme – Art 5 of MAR – Week 26 – 2024
02 July 2024
9 mins read
Ipsen expands collaboration and license agreement for development of Cabometyx® in advanced neuroendocrine tumors based on positive CABINET Phase III trial
18 June 2024
1 mins read
IPSEN – Buy-back programme – Art 5 of MAR – Week 24 – 2024
11 June 2024
1 mins read
IPSEN – Buy-back programme – Art 5 of MAR – Week 23 – 2024
10 June 2024
12 mins read
Ipsen’s Iqirvo® receives U.S. FDA accelerated approval as a first-in-class PPAR treatment for primary biliary cholangitis
07 June 2024
6 mins read